AC Immune reports clinical milestones for ACI-24 vaccine in Alzheimer’s disease and Down Syndrome

Image: AC Immune’s phase 2 study will assess the safety, tolerability, immunogenicity, target engagement, biomarkers and clinical efficacy of ACI-24. Photo: courtesy of suphakit73 / FreeDigitalPhotos.net.